GENENTECH, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study to Evaluate MILR1444A in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma
- First Posted Date
- 2008-10-29
- Last Posted Date
- 2010-05-06
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT00781443
The Safety and Utility of Skin Testing With XOLAIR® (Omalizumab) and Placebo Omalizumab (Formulation Excipients)
Phase 4
Completed
- Conditions
- HealthyAsthma
- Interventions
- Drug: Cohort 2Drug: Cohort I
- First Posted Date
- 2008-10-22
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT00777764
A Study of D4064A Administered to Patients With Recurrent or Persistent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase 1
Suspended
- Conditions
- Fallopian Tube CancerOvarian CancerPeritoneal Cancer
- First Posted Date
- 2008-09-16
- Last Posted Date
- 2008-11-07
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT00753480
- Locations
- 🇺🇸
Investigational Site, Nashville, Tennessee, United States
A Study of MNRP1685A in Patients With Locally Advanced or Metastatic Solid Tumors
Phase 1
Completed
- Conditions
- Solid Cancers
- First Posted Date
- 2008-09-05
- Last Posted Date
- 2011-04-20
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT00747734
A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission
Phase 2
Completed
- Conditions
- Ovarian Cancer
- Interventions
- First Posted Date
- 2008-08-22
- Last Posted Date
- 2017-06-08
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 104
- Registration Number
- NCT00739661
A Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anti-Abeta (MABT5102A) in Patients With Alzheimer's Disease
Phase 1
Completed
- Conditions
- Alzheimer's Disease
- First Posted Date
- 2008-08-18
- Last Posted Date
- 2010-10-27
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT00736775
A Study to Evaluate Efalizumab Compared With Cyclosporine As an Immunosuppressant Regimen in De Novo Renal Transplantation
Phase 2
Withdrawn
- Conditions
- Kidney Transplantation
- Interventions
- First Posted Date
- 2008-08-07
- Last Posted Date
- 2017-06-22
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT00729768
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2008-08-01
- Last Posted Date
- 2017-07-11
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 1287
- Registration Number
- NCT00726661
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE)
Phase 3
Completed
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- Drug: CVP (cyclophosphamide, vincristine, prednisone)Drug: Analgesic/antipyretic and antihistamine drugs
- First Posted Date
- 2008-07-21
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 451
- Registration Number
- NCT00719472
A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of MTRX1011A in Patients With Rheumatoid Arthritis
Phase 1
Terminated
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2008-07-18
- Last Posted Date
- 2012-03-07
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 66
- Registration Number
- NCT00718588
© Copyright 2025. All Rights Reserved by MedPath